An Integrated Intervention Using a Pill Ingestible Sensor System

Last updated: February 6, 2025
Sponsor: University of California, Los Angeles
Overall Status: Active - Recruiting

Phase

2

Condition

Hiv Infections

Hiv/aids

Aids And Aids Related Infections

Treatment

ISS-SBDOH arm

Clinical Study ID

NCT06480578
R01MD019188
R01MD019188
  • Ages > 18
  • All Genders

Study Summary

This study integrates technology-based adherence measures with alerts for social and behavioral determinants of health (SBDOH) to improve HIV treatment outcomes. It involves 110 adult patients from a Los Angeles County HIV clinic, focusing on those at risk for poor adherence. Participants will be randomized into intervention or usual care groups, with endpoints including intervention acceptability, SBDOH interventions, adherence to ART, viral load, and high-risk sexual activity. The study aims to assess the effectiveness of the integrated intervention in improving adherence, virologic outcomes, and reducing high-risk behavior among PLWH.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. HIV-infected individuals in HIV care

  2. Greater than 17 years of age

  3. Demonstrated ability to take co-encapsulated ARVs at the time of screening

  4. Able to provide informed consent

  5. Receiving ART with sub-optimal adherence estimated by patient (self-reports < 90%adherence over last 28 days) or treating clinician [e.g., based on gaps in treatment (e.g. missed appointments) or viral load elevations within 6 months], or at highrisk for sub-optimal adherence, or with known challenges with SBDOH (e.g. unstablehousing, substance use disorder, and poverty

  6. Currently receiving antiretroviral treatment that includes one of the following:

  • TDF/FTC (Truvada)

  • TAF/FTC (Descovy)

  • EFV/FTC/TDF (Atripla)

  • ABC/3TC (Epzicom)

  • DTG/ABC/3TC (Triumeq)

  • RPV/TAF/FTC (Odefsey)

  • EVG/c/FTC/TAF (Genvoya)

  • BIC/FTC/TAF (Biktarvy)

  1. For participants of reproductive potential, negative serum or urine pregnancy testwith a sensitivity of ≤25 mIU/mL at screening. This will be repeated again at studyentry.

NOTE: Participants are considered to be NOT of reproductive potential if:

  1. participants have had amenorrhea for at least 12 consecutive months prior to studyentry (i.e., who have had no menses within 12 months prior to study entry), and havea documented FSH >40 IU/mL; OR

  2. an FSH level is not available, but participants have had 24 consecutive months ofamenorrhea (in the absence of medications known to induce amenorrhea); OR

  3. participants report having undergone surgical sterilization (e.g., hysterectomy, orbilateral oophorectomy, or bilateral tubal ligation/hysteroscopic tubal occlusion).

Exclusion

Exclusion Criteria:

  1. Inability to follow the study procedures manifested during the intake, as evidencedby mental confusion, disorganization, intoxication, withdrawal, risky or threateningbehavior

  2. Pregnancy (Evaluated during the screening visit through a pregnancy test.)

Study Design

Total Participants: 110
Treatment Group(s): 1
Primary Treatment: ISS-SBDOH arm
Phase: 2
Study Start date:
December 19, 2024
Estimated Completion Date:
December 31, 2027

Study Description

Undetectable equals Untransmittable (U=U) reduces HIV stigma, empowers people living with HIV (PLWH), and has become a pillar in the goal of ending the HIV epidemic. Viral suppression eliminating risk of sexual HIV transmission emphasizes the importance of adherence to antiretroviral therapy (ART). Strategies to enhance adherence have typically not intervened in real-time and have focused on pill-taking reminders without interventions that address adverse social and behavioral determinants of health (SBDOH) associated with poor adherence and engagement in care. The complex multifactorial pathways of SBDOH, such as food insecurity, unstable housing, and substance use disorders, have led to inequities in achieving optimal adherence and sustained viral suppression. Los Angeles (LA) County, a hot spot for HIV infection and transmission, has been reported to have viral suppression rates of ~60%, well below the 95% target of Ending HIV Epidemic by 2030. Our team has an extensive track record of research on measurement of and interventions to enhance adherence to ART. The investigators have used novel technology-based adherence measures of ART developed in the past two decades, including the cutting-edge ingestible sensor (IS) technology to obtain non-inferred, real-time adherence monitoring by Proteus® Digital Health Feedback (PDHF) system. Despite its validation reported in our recent publications, the PDHF system has been limited by the lack of incorporation of SBDOH. For many years, a major focus in HIV clinics has been to have multidisciplinary teams of nurses, social workers, and case managers to address SBDOH; however, timing of interventions are often weeks to months after such problems have been identified. This study will develop and test an integrated intervention that combines IS technology and adverse SBDOH alerts to maximize adherence and viral suppression. Using real-time IS monitoring, our integrated intervention will be able to immediately trigger the existing multidisciplinary team at clinic to address SBDOH issues as soon as predefined patterns of poor adherence are observed. A cohort of 110 adult patients who have or are at high risk for sub-optimal adherence will be recruited from a LA County safety net HIV clinic, located in a geographic HIV hotspot, dealing many adverse SBDOH issues. Participants will be randomized into the intervention or usual care. The integrated intervention will run for 20 weeks, followed by a 10-week period to assess sustainability. The primary end points include acceptability of the integrated intervention, frequency and timeliness of SBDOH interventions, level of challenges of SBDOH in HIV treatment, and adherence to ART. The secondary end points include viral load, high-risk sexual activity defined by self-report, and detection of sexually transmitted infections. The overarching goals are to evaluate (i) acceptability of the integrated intervention, frequency and timeliness of SBDOH intervention, and level of challenges of SBDOH in HIV treatment; (ii) the efficacy of the integrated intervention for monitoring, facilitating, and improving adherence to ART; and (iii) the efficacy of the integrated intervention for improving virologic outcome and reducing high-risk sexual activity.

Connect with a study center

  • Lundquist

    Los Angeles, California 90502
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.